Acadia Healthcare Reports Third Quarter 2022 Results
Acadia Healthcare Company (NASDAQ: ACHC) reported a 13.5% increase in revenue, totaling $666.7 million for Q3 2022, compared to the same quarter last year. Same-facility revenue rose 10.2%, driven by a 6.9% increase in revenue per patient day. Net income was $71.1 million ($0.78 per share), and adjusted EBITDA reached $162.8 million. The company opened new facilities, including a children's hospital in Chicago, and continues to expand its service offerings. Financial guidance for 2022 is narrowed, estimating revenue between $2.58 billion and $2.60 billion.
- Revenue increased by 13.5% to $666.7 million in Q3 2022.
- Same-facility revenue grew by 10.2%, driven by 6.9% higher revenue per patient day.
- Net income attributable to Acadia was $71.1 million, or $0.78 per diluted share.
- Adjusted EBITDA for Q3 was $162.8 million, up from $141.9 million year-over-year.
- Opened new facilities, including a children's hospital and Comprehensive Treatment Centers.
- Income from the Provider Relief Fund accounted for $7.7 million in adjusted EBITDA.
- Excluding income from the PRF, adjusted earnings per diluted share was only $0.80.
Same Facility Revenue Increases
Third Quarter Highlights
-
Revenue totaled
, an increase of$666.7 million 13.5% over the third quarter of 2021 -
Same facility revenue increased
10.2% compared to the third quarter of 2021, including an increase in revenue per patient day of6.9% and an increase in patient days of3.1% -
Net income attributable to Acadia totaled
, or$71.1 million per diluted share, and adjusted income from continuing operations attributable to Acadia stockholders totaled$0.78 , or$73.3 million per diluted share, which included$0.86 of income from the$0.06 Provider Relief Fund (“PRF”) established under the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act -
Adjusted EBITDA totaled
, which included$162.8 million of income from the PRF established under the CARES Act$7.7 million -
Opened a de novo children’s hospital in
Chicago , a joint venture facility inKnoxville , and two new Comprehensive Treatment Centers (“CTCs”)
Third Quarter Results
The Company reported revenue of
The Company recorded income from the PRF of
Net income attributable to Acadia stockholders for the third quarter of 2022 was
For the third quarter of 2022, Acadia’s same facility revenue increased
Strategic Investments for Long-Term Growth
“We have progressed on our key growth initiatives across all our service lines this year. We continue to make critical investments in our business to support sustained long-term growth through four distinct pathways. Facility expansions are our first and most efficient growth pathway as we can expand services in established markets with our existing infrastructure and experienced staff. We added 132 beds to our existing facilities during the third quarter, bringing our total number of bed additions to 210 for the first nine months of the year. We are on track to meet our goal of adding approximately 300 beds in 2022.
“For our second growth pathway, we continue to develop wholly owned de novo facilities that meet the critical demand for behavioral healthcare services in underserved markets. There are significant opportunities across the country to address this unmet need at the local community level. We opened a 60-bed children’s hospital in early July, as the first stage of our
“We continue to identify opportunities to expand our network of CTCs to address the critical need for addiction treatment, specifically for patients dealing with opioid use disorder. During the third quarter, we opened new CTCs in
“A third important pathway for growth for Acadia is forming strategic partnerships with leading health systems across the country. We are proud to work with a growing number of premier health systems to expand behavioral healthcare treatment options in their respective communities. By working together, we can leverage our behavioral health expertise and implement best practices to deliver high quality care and positive clinical outcomes for more patients. During the third quarter, we opened a new facility with our joint venture partner,
“For our fourth pathway, we focus on identifying strategic acquisition opportunities that allow us to leverage our scale and expertise, make necessary investments for expansion and add service offerings to further enhance the continuum of care. We are fortunate to have a strong balance sheet that supports our ability to pursue acquisitions along with opportunities through our other important growth pathways,” added Hunter.
Cash and Liquidity
Maintaining a strong financial position is a top priority for Acadia, providing the flexibility to pursue its growth initiatives and make strategic investments in its business. As of
During the third quarter, the Company substantially completed its repayment of amounts received pursuant to the Medicare Accelerated and Advanced Payment Program under the CARES Act. Of the
Financial Guidance
Acadia today narrowed its previously announced financial guidance for 2022, as follows:
|
2022 |
|||
Revenue |
|
|||
Adjusted EBITDA, including income from the PRF |
|
|||
Adjusted EBITDA, excluding income from the PRF |
|
|||
Adjusted earnings per diluted share, including |
||||
income from the PRF |
|
|||
Adjusted earnings per diluted share, excluding |
||||
income from the PRF |
|
|||
Interest expense |
Approximately |
|||
Tax rate |
|
|||
Depreciation and amortization expense |
Approximately |
|||
Stock compensation expense |
Approximately |
|||
Operating cash flows |
|
|||
Expansion capital expenditures |
|
|||
Maintenance capital expenditures |
Approximately |
The Company’s guidance does not include the impact of any future acquisitions, divestitures or transaction-related expenses.
Looking Ahead
Hunter added, “We look forward to hosting Acadia’s first Investor Day on
“We are excited about the opportunities ahead for Acadia, as we remain focused on our primary objective to extend our market reach through our four defined growth pathways. Demand for our services continues to grow, and we believe we are well positioned to maintain our strong growth trajectory and meet our development targets for the year. Without question, the critical need for behavioral health treatment has become a primary focus for health officials, medical professionals, and lawmakers across the country, with depression and anxiety issues further amplified by the strains of the COVID-19 pandemic. Recent data from the
Conference Call
Acadia will hold a conference call to discuss its third quarter financial results at
About Acadia
Acadia is a leading provider of behavioral healthcare services across
Forward-Looking Information
This press release contains forward-looking statements. Generally, words such as “may,” “will,” “should,” “could,” “anticipate,” “expect,” “intend,” “estimate,” “plan,” “continue,” and “believe” or the negative of or other variation on these and other similar expressions identify forward-looking statements. These forward-looking statements are made only as of the date of this press release. We do not undertake to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are based on current expectations and involve risks and uncertainties and our future results could differ significantly from those expressed or implied by our forward-looking statements. Factors that may cause actual results to differ materially include, without limitation, (i) the impact of the COVID-19 pandemic, including, without limitation, disruption to the
Condensed Consolidated Statements of Operations | |||||||||||||||||
(Unaudited) | |||||||||||||||||
Three Months Ended |
|
Nine Months Ended |
|||||||||||||||
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
|||
(In thousands, except per share amounts) | |||||||||||||||||
Revenue | $ |
666,732 |
|
$ |
587,559 |
|
$ |
1,935,104 |
|
$ |
1,720,914 |
|
|||||
Salaries, wages and benefits (including equity-based compensation expense of |
|
352,582 |
|
|
309,118 |
|
|
1,027,732 |
|
|
922,684 |
|
|||||
Professional fees |
|
40,367 |
|
|
35,602 |
|
|
117,718 |
|
|
101,915 |
|
|||||
Supplies |
|
25,570 |
|
|
23,743 |
|
|
74,291 |
|
|
67,698 |
|
|||||
Rents and leases |
|
11,339 |
|
|
9,658 |
|
|
33,780 |
|
|
28,690 |
|
|||||
Other operating expenses |
|
88,993 |
|
|
76,502 |
|
|
255,355 |
|
|
222,263 |
|
|||||
Income from provider relief fund |
|
(7,656 |
) |
|
— |
|
|
(16,206 |
) |
|
— |
|
|||||
Depreciation and amortization |
|
29,573 |
|
|
27,805 |
|
|
87,627 |
|
|
78,349 |
|
|||||
Interest expense, net |
|
18,003 |
|
|
15,706 |
|
|
50,355 |
|
|
61,420 |
|
|||||
Debt extinguishment costs |
|
— |
|
|
— |
|
|
— |
|
|
24,650 |
|
|||||
Loss on impairment |
|
— |
|
|
1,079 |
|
|
— |
|
|
24,293 |
|
|||||
Transaction-related expenses |
|
10,859 |
|
|
3,035 |
|
|
18,381 |
|
|
9,320 |
|
|||||
Total expenses |
|
569,630 |
|
|
502,248 |
|
|
1,649,033 |
|
|
1,541,282 |
|
|||||
Income from continuing operations before income taxes |
|
97,102 |
|
|
85,311 |
|
|
286,071 |
|
|
179,632 |
|
|||||
Provision for income taxes |
|
24,056 |
|
|
17,411 |
|
|
69,183 |
|
|
42,948 |
|
|||||
Income from continuing operations |
|
73,046 |
|
|
67,900 |
|
|
216,888 |
|
|
136,684 |
|
|||||
Loss from discontinued operations, net of taxes |
|
— |
|
|
— |
|
|
— |
|
|
(12,641 |
) |
|||||
Net income |
|
73,046 |
|
|
67,900 |
|
|
216,888 |
|
|
124,043 |
|
|||||
Net income attributable to noncontrolling interests |
|
(1,947 |
) |
|
(1,774 |
) |
|
(4,873 |
) |
|
(3,686 |
) |
|||||
Net income attributable to |
$ |
71,099 |
|
$ |
66,126 |
|
$ |
212,015 |
|
$ |
120,357 |
|
|||||
Basic earnings per share attributable to |
|||||||||||||||||
Income from continuing operations attributable to |
$ |
0.79 |
|
$ |
0.74 |
|
$ |
2.37 |
|
$ |
1.50 |
|
|||||
Loss from discontinued operations |
|
— |
|
|
— |
|
|
— |
|
$ |
(0.14 |
) |
|||||
Net income attributable to |
$ |
0.79 |
|
$ |
0.74 |
|
$ |
2.37 |
|
$ |
1.36 |
|
|||||
Diluted earnings per share attributable to |
|||||||||||||||||
Income from continuing operations attributable to |
$ |
0.78 |
|
$ |
0.73 |
|
$ |
2.31 |
|
$ |
1.47 |
|
|||||
Loss from discontinued operations |
|
— |
|
|
— |
|
|
— |
|
$ |
(0.14 |
) |
|||||
Net income attributable to |
$ |
0.78 |
|
$ |
0.73 |
|
$ |
2.31 |
|
$ |
1.33 |
|
|||||
Weighted-average shares outstanding: | |||||||||||||||||
Basic |
|
89,833 |
|
|
88,962 |
|
|
89,607 |
|
|
88,684 |
|
|||||
Diluted |
|
91,723 |
|
|
90,889 |
|
|
91,668 |
|
|
90,604 |
|
Condensed Consolidated Balance Sheets | ||||||||
(Unaudited) | ||||||||
|
|
|
||||||
2022 |
|
2021 |
||||||
(In thousands) |
||||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ |
93,419 |
$ |
133,813 |
|
|||
Accounts receivable, net |
|
315,999 |
|
281,332 |
|
|||
Other current assets |
|
112,238 |
|
79,886 |
|
|||
Total current assets |
|
521,656 |
|
495,031 |
|
|||
Property and equipment, net |
|
1,908,993 |
|
1,771,159 |
|
|||
|
2,207,912 |
|
2,199,937 |
|
||||
Intangible assets, net |
|
75,920 |
|
70,145 |
|
|||
Deferred tax assets |
|
2,983 |
|
3,080 |
|
|||
Operating lease right-of-use assets |
|
135,627 |
|
133,761 |
|
|||
Other assets |
|
90,014 |
|
94,965 |
|
|||
Total assets | $ |
4,943,105 |
$ |
4,768,078 |
|
|||
LIABILITIES AND EQUITY | ||||||||
Current liabilities: | ||||||||
Current portion of long-term debt | $ |
21,250 |
$ |
18,594 |
|
|||
Accounts payable |
|
116,045 |
|
98,575 |
|
|||
Accrued salaries and benefits |
|
109,654 |
|
137,845 |
|
|||
Current portion of operating lease liabilities |
|
25,770 |
|
23,348 |
|
|||
Other accrued liabilities |
|
128,294 |
|
126,499 |
|
|||
Total current liabilities |
|
401,013 |
|
404,861 |
|
|||
Long-term debt |
|
1,379,306 |
|
1,478,626 |
|
|||
Deferred tax liabilities |
|
94,446 |
|
74,368 |
|
|||
Operating lease liabilities |
|
117,473 |
|
116,841 |
|
|||
Other liabilities |
|
118,923 |
|
110,505 |
|
|||
Total liabilities |
|
2,111,161 |
|
2,185,201 |
|
|||
Redeemable noncontrolling interests |
|
88,236 |
|
65,388 |
|
|||
Equity: | ||||||||
Common stock |
|
899 |
|
890 |
|
|||
Additional paid-in capital |
|
2,650,545 |
|
2,636,350 |
|
|||
Retained earnings (accumulated deficit) |
|
92,264 |
|
(119,751 |
) |
|||
Total equity |
|
2,743,708 |
|
2,517,489 |
|
|||
Total liabilities and equity | $ |
4,943,105 |
$ |
4,768,078 |
|
Condensed Consolidated Statements of Cash Flows | |||||||||
(Unaudited) | |||||||||
Nine Months Ended |
|||||||||
|
2022 |
|
|
|
2021 |
|
|||
(In thousands) | |||||||||
Operating activities: | |||||||||
Net income | $ |
216,888 |
|
$ |
124,043 |
|
|||
Adjustments to reconcile net income to net cash provided by continuing operating activities: | |||||||||
Depreciation and amortization |
|
87,627 |
|
|
78,349 |
|
|||
Amortization of debt issuance costs |
|
2,440 |
|
|
3,265 |
|
|||
Equity-based compensation expense |
|
21,745 |
|
|
24,988 |
|
|||
Deferred income taxes |
|
20,176 |
|
|
8,995 |
|
|||
Loss from discontinued operations, net of taxes |
|
— |
|
|
12,641 |
|
|||
Debt extinguishment costs |
|
— |
|
|
24,650 |
|
|||
Loss on impairment |
|
— |
|
|
24,293 |
|
|||
Other |
|
2,422 |
|
|
881 |
|
|||
Change in operating assets and liabilities, net of effect of acquisitions: | |||||||||
Accounts receivable, net |
|
(35,538 |
) |
|
(8,610 |
) |
|||
Other current assets |
|
(28,692 |
) |
|
(2,758 |
) |
|||
Other assets |
|
3,373 |
|
|
(15,846 |
) |
|||
Accounts payable and other accrued liabilities |
|
7,729 |
|
|
6,358 |
|
|||
Accrued salaries and benefits |
|
(8,831 |
) |
|
18,820 |
|
|||
Other liabilities |
|
10,303 |
|
|
(11,633 |
) |
|||
Government relief funds |
|
(32,617 |
) |
|
(12,058 |
) |
|||
Net cash provided by continuing operating activities |
|
267,025 |
|
|
276,378 |
|
|||
Net cash provided by discontinued operating activities |
|
— |
|
|
253 |
|
|||
Net cash provided by operating activities |
|
267,025 |
|
|
276,631 |
|
|||
Investing activities: | |||||||||
Cash paid for capital expenditures |
|
(208,792 |
) |
|
(156,624 |
) |
|||
Proceeds from U. |
|
— |
|
|
1,511,020 |
|
|||
Settlement of foreign currency derivatives |
|
— |
|
|
(84,795 |
) |
|||
Proceeds from sale of property and equipment |
|
1,784 |
|
|
1,792 |
|
|||
Cash paid for purchase of finance lease |
|
— |
|
|
(31,401 |
) |
|||
Other |
|
(6,802 |
) |
|
3,106 |
|
|||
Net cash (used in) provided by investing activities |
|
(213,810 |
) |
|
1,243,098 |
|
|||
Financing activities: | |||||||||
Borrowings on long-term debt |
|
— |
|
|
425,000 |
|
|||
Borrowings on revolving credit facility |
|
— |
|
|
430,000 |
|
|||
Principal payments on revolving credit facility |
|
(85,000 |
) |
|
(330,000 |
) |
|||
Principal payments on long-term debt |
|
(13,281 |
) |
|
(5,313 |
) |
|||
Repayment of long-term debt |
|
— |
|
|
(2,227,935 |
) |
|||
Payment of debt issuance costs |
|
— |
|
|
(7,964 |
) |
|||
Repurchase of shares for payroll tax withholding, net of proceeds from stock option exercises |
|
(7,541 |
) |
|
16,072 |
|
|||
Contributions from noncontrolling partners in joint ventures |
|
13,178 |
|
|
1,800 |
|
|||
Distributions to noncontrolling partners in joint ventures |
|
(1,004 |
) |
|
(926 |
) |
|||
Other |
|
39 |
|
|
(6,914 |
) |
|||
Net cash used in financing activities |
|
(93,609 |
) |
|
(1,706,180 |
) |
|||
Effect of exchange rate changes on cash |
|
— |
|
|
4,067 |
|
|||
Net decrease in cash and cash equivalents |
|
(40,394 |
) |
|
(182,384 |
) |
|||
Cash and cash equivalents at beginning of the period |
|
133,813 |
|
|
378,697 |
|
|||
Cash and cash equivalents at end of the period | $ |
93,419 |
|
$ |
196,313 |
|
Operating Statistics | |||||||||||||||||||||||
(Unaudited, Revenue in thousands) | |||||||||||||||||||||||
Three Months Ended |
|
Nine Months Ended |
|||||||||||||||||||||
|
2022 |
|
|
|
2021 |
|
|
% Change |
|
|
2022 |
|
|
|
2021 |
|
|
% Change |
|||||
Revenue | $ |
640,343 |
|
$ |
580,930 |
|
10.2 |
% |
$ |
1,859,200 |
|
$ |
1,703,906 |
|
9.1 |
% |
|||||||
|
713,531 |
|
|
691,956 |
|
3.1 |
% |
|
2,110,129 |
|
|
2,068,842 |
|
2.0 |
% |
||||||||
Admissions |
|
45,445 |
|
|
45,192 |
|
0.6 |
% |
|
133,204 |
|
|
136,183 |
|
-2.2 |
% |
|||||||
Average Length of Stay (2) |
|
15.7 |
|
|
15.3 |
|
2.5 |
% |
|
15.8 |
|
|
15.2 |
|
4.3 |
% |
|||||||
Revenue per |
$ |
897 |
|
$ |
840 |
|
6.9 |
% |
$ |
881 |
|
$ |
824 |
|
7.0 |
% |
|||||||
Adjusted EBITDA margin (3) |
|
30.5 |
% |
|
29.0 |
% |
150 bps |
|
29.9 |
% |
|
28.0 |
% |
190 bps | |||||||||
Adjusted EBITDA margin excluding income from provider relief fund |
|
29.3 |
% |
|
29.0 |
% |
30 bps |
|
29.0 |
% |
|
28.0 |
% |
100 bps | |||||||||
Revenue | $ |
666,732 |
|
$ |
587,559 |
|
13.5 |
% |
$ |
1,935,104 |
|
$ |
1,720,914 |
|
12.4 |
% |
|||||||
|
738,702 |
|
|
701,352 |
|
5.3 |
% |
|
2,179,805 |
|
|
2,088,477 |
|
4.4 |
% |
||||||||
Admissions |
|
47,692 |
|
|
45,246 |
|
5.4 |
% |
|
139,930 |
|
|
136,384 |
|
2.6 |
% |
|||||||
Average Length of Stay (2) |
|
15.5 |
|
|
15.5 |
|
-0.1 |
% |
|
15.6 |
|
|
15.3 |
|
1.7 |
% |
|||||||
Revenue per |
$ |
903 |
|
$ |
838 |
|
7.7 |
% |
$ |
888 |
|
$ |
824 |
|
7.7 |
% |
|||||||
Adjusted EBITDA margin (3) |
|
28.7 |
% |
|
28.3 |
% |
40 bps |
|
28.3 |
% |
|
27.7 |
% |
60 bps | |||||||||
Adjusted EBITDA margin excluding income from provider relief fund |
|
27.5 |
% |
|
28.3 |
% |
-80 bps |
|
27.4 |
% |
|
27.7 |
% |
-30 bps | |||||||||
(1) Same facility results for the periods presented include facilities we have operated for more than one year and exclude certain closed services. | |||||||||||||||||||||||
(2) Average length of stay is defined as patient days divided by admissions. | |||||||||||||||||||||||
(3) For the three and nine months ended |
Reconciliation of Net Income Attributable to |
||||||||||||||||
(Unaudited) | ||||||||||||||||
Three Months Ended |
|
Nine Months Ended |
||||||||||||||
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
||
(in thousands) | ||||||||||||||||
Net income attributable to |
$ |
71,099 |
|
$ |
66,126 |
|
$ |
212,015 |
|
$ |
120,357 |
|
||||
Net income attributable to noncontrolling interests |
|
1,947 |
|
|
1,774 |
|
|
4,873 |
|
|
3,686 |
|
||||
Loss from discontinued operations, net of taxes |
|
— |
|
|
— |
|
|
— |
|
|
12,641 |
|
||||
Provision for income taxes |
|
24,056 |
|
|
17,411 |
|
|
69,183 |
|
|
42,948 |
|
||||
Interest expense, net |
|
18,003 |
|
|
15,706 |
|
|
50,355 |
|
|
61,420 |
|
||||
Depreciation and amortization |
|
29,573 |
|
|
27,805 |
|
|
87,627 |
|
|
78,349 |
|
||||
EBITDA |
|
144,678 |
|
|
128,822 |
|
|
424,053 |
|
|
319,401 |
|
||||
Adjustments: | ||||||||||||||||
Equity-based compensation expense (a) |
|
7,240 |
|
|
8,923 |
|
|
21,745 |
|
|
24,988 |
|
||||
Transaction-related expenses (b) |
|
10,859 |
|
|
3,035 |
|
|
18,381 |
|
|
9,320 |
|
||||
Debt extinguishment costs (c) |
|
— |
|
|
— |
|
|
— |
|
|
24,650 |
|
||||
Loss on impairment (d) |
|
— |
|
|
1,079 |
|
|
— |
|
|
24,293 |
|
||||
Adjusted EBITDA | $ |
162,777 |
|
$ |
141,859 |
|
$ |
464,179 |
|
$ |
402,652 |
|
||||
Adjusted EBITDA margin |
|
24.4 |
% |
|
24.1 |
% |
|
24.0 |
% |
|
23.4 |
% |
||||
Adjusted EBITDA excluding income from provider relief fund | $ |
155,121 |
|
$ |
141,859 |
|
$ |
447,973 |
|
$ |
402,652 |
|
||||
Adjusted EBITDA margin excluding income from provider relief fund |
|
23.3 |
% |
|
24.1 |
% |
|
23.1 |
% |
|
23.4 |
% |
||||
See footnotes on page 12. |
Reconciliation of Net Income Attributable to |
||||||||||||||
Adjusted Income Attributable to |
||||||||||||||
(Unaudited) | ||||||||||||||
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
2022 |
|
|
|
2021 |
|
|
2022 |
|
|
|
2021 |
||
(in thousands, except per share amounts) | ||||||||||||||
Net income attributable to |
$ |
71,099 |
|
$ |
66,126 |
$ |
212,015 |
|
$ |
120,357 |
||||
Loss from discontinued operations, net of taxes |
|
— |
|
|
— |
|
— |
|
|
12,641 |
||||
Adjustments to income: | ||||||||||||||
Transaction-related expenses (b) |
|
10,859 |
|
|
3,035 |
|
18,381 |
|
|
9,320 |
||||
Debt extinguishment costs (c) |
|
— |
|
|
— |
|
— |
|
|
24,650 |
||||
Loss on impairment (d) |
|
— |
|
|
1,079 |
|
— |
|
|
24,293 |
||||
Provision for income taxes |
|
24,056 |
|
|
17,411 |
|
69,183 |
|
|
42,948 |
||||
Adjusted income from continuing operations before income taxes attributable to |
|
106,014 |
|
|
87,651 |
|
299,579 |
|
|
234,209 |
||||
Income tax effect of adjustments to income (e) |
|
(49,514 |
) |
|
22,508 |
|
- |
|
|
62,709 |
||||
Adjusted income from continuing operations attributable to |
|
155,528 |
|
|
65,143 |
|
299,579 |
|
|
171,500 |
||||
Income from provider relief fund, net of taxes |
|
(5,579 |
) |
|
— |
|
(11,809 |
) |
|
— |
||||
Adjusted income from continuing operations attributable to |
$ |
149,949 |
|
$ |
65,143 |
$ |
287,770 |
|
$ |
171,500 |
||||
Weighted-average shares outstanding - diluted |
|
91,723 |
|
|
90,889 |
|
91,668 |
|
|
90,604 |
||||
Adjusted income from continuing operations attributable to |
$ |
1.70 |
|
$ |
0.72 |
$ |
3.27 |
|
$ |
1.89 |
||||
Income from provider relief fund, net of taxes, per diluted share |
|
(0.06 |
) |
|
— |
|
(0.13 |
) |
|
— |
||||
Adjusted income from continuing operations attributable to |
$ |
1.64 |
|
$ |
0.72 |
$ |
3.14 |
|
$ |
1.89 |
||||
See footnotes on page 12. |
Footnotes | |||||||||||
We have included certain financial measures in this press release, including those listed below, which are “non-GAAP financial measures” as defined under the rules and regulations promulgated by the |
|||||||||||
• EBITDA: net income attributable to |
|||||||||||
• Adjusted EBITDA: EBITDA adjusted for equity-based compensation expense, transaction-related expenses, debt extinguishment costs and loss on impairment. | |||||||||||
• Adjusted EBITDA excluding income from provider relief fund: Adjusted EBITDA adjusted for income from provider relief fund. | |||||||||||
• Adjusted EBITDA margin: Adjusted EBITDA divided by revenue. | |||||||||||
• Adjusted EBITDA margin excluding income from provider relief fund: Adjusted EBITDA excluding income from provider relief fund divided by revenue. | |||||||||||
• Adjusted income from continuing operations before income taxes attributable to |
|||||||||||
• Adjusted income from continuing operations attributable to |
|||||||||||
• Adjusted income from continuing operations attributable to |
|||||||||||
• Adjusted income attributable to |
|||||||||||
• Adjusted income attributable to |
|||||||||||
The non-GAAP financial measures presented herein are supplemental measures of our performance and are not required by, or presented in accordance with, generally accepted accounting principles in |
|||||||||||
The Company is not able to provide a reconciliation of projected Adjusted EBITDA and adjusted earnings per diluted share, where provided and whether including or excluding income from provider relief fund, to expected results due to the unknown effect, timing and potential significance of transaction-related expenses and the tax effect of such expenses. | |||||||||||
(a) Represents the equity-based compensation expense of Acadia. | |||||||||||
(b) Represents transaction-related expenses incurred by Acadia primarily related to termination, restructuring, management transition, acquisition and other similar costs. | |||||||||||
(c) Represents debt extinguishment costs recorded during the first quarter of 2021 in connection with the redemption of the |
|||||||||||
(d) The Company opened a 260-bed replacement hospital in |
|||||||||||
(e) Represents the income tax effect of adjustments to income based on tax rates of |
View source version on businesswire.com: https://www.businesswire.com/news/home/20221031005654/en/
Vice President, Investor Relations
(615) 861-6000
Source:
FAQ
What were Acadia Healthcare's Q3 2022 financial results?
How much did Acadia Healthcare's same facility revenue increase in Q3 2022?
What is the adjusted EBITDA for Acadia Healthcare in Q3 2022?
What is Acadia Healthcare's financial guidance for 2022?